Insights & Blog

GLP‑1 Drug Surge: How Employers Are Managing Rising Costs in 2025

GLP‑1 medications such as Ozempic®, Wegovy®, and Zepbound®—originally developed to treat Type 2 diabetes—have rapidly become some of the most prescribed drugs for weight management. While their...

Student Loan and Education Assistance Benefits: Dual Strategies to Reduce Turnover and Build Workforce Loyalty

Attracting and retaining talent in 2025 requires more than compensation—it demands meaningful, sustainable benefits that address the real-world financial pressures employees face. Education-related...

Small Businesses vs. Big RTO Mandates: Flexibility as a Competitive Advantage

As the business landscape evolves in 2025, employers are facing significant pressures related to Return to Office (RTO) mandates, especially from larger companies enforcing rigid work models. However...

Mental Health Parity Developments: Navigating the ERIC Lawsuit and DOJ Enforcement Pause

In the first half of 2025, several pivotal developments involving the Mental Health Parity and Addiction Equity Act (MHPAEA) have emerged that carry significant implications for employers, including...

Elimination of the Federal Insurance Office (FIO): Implications for Insurance Regulation

In an era where regulatory complexity and insurance innovation are evolving rapidly, a low-profile but potentially seismic shift is underway in Washington, D.C. In January 2025, Congress reintroduced...

The PBM Shake-Up: How 2025’s Transparency Rules Are Reshaping Pharmacy Contracts and Drug Costs

2025 is proving to be a transformative year for pharmacy benefits management. New federal transparency requirements are shining a spotlight on Pharmacy Benefit Managers (PBMs), forcing these powerful...

Want to know more about Atria?